RAB17

Across TCGA pan-cancer cohorts, RAB17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAB17 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAB17 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB17 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where RAB17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.937	0.504	<.001	49	view →
UCEC	OS	Median	All	1.000	0.897	.007	4	view →
LSCC	OS	Quartile	II,III,IV	0.517	0.853	.049	2	view →
PDAC	DFS	Median	II,III,IV	0.512	0.271	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAB17–CCRCC (DFS)

Open the CCRCC breakdown →